

[319] NEURONIX TECHNOLOGY FOR TREATMENT OF ALZHEIMER'S DISEASE - RESULTS OF PHASE-III US MULTI-CENTER STUDY

Eyal Baror¹, Moran Ploznik¹, ¹ Neuronix

- **Investment Rational**
With aging population, Alzheimer's disease represents one of the greatest healthcare challenges today. It is the only disease of the top 10-killers in the USA, which cannot be prevented, cured or even slowed down. Neuronix, an Israeli company, has developed the neuroAD™— the only clinically proven, medical device technology offering an effective treatment for mild to moderate Alzheimer's disease.
- **Business Strategy**
The neuroAD™ is CE-marked and available in selected clinics across the world. The neuroAD™ has been submitted for US-FDA de-novo marketing clearance under the expedited access pathway (EAP), following a successful Phase-III, US Multi-Center Pivotal Study. Clearance is expected during 2017Q4.
- **Core Technology**
Neuronix patented technology combines accurate delivery of noninvasive Transcranial Magnetic Stimulation (TMS) to selected cortical brain regions, concurrently with tailor-made cognitive training that engages those specific regions. In several clinical studies, performed in world leading institutions, including most recently a Phase-III, US Multi-Center Pivotal Study, the neuroAD™ was proven safe and effective in treatment of mild to moderate Alzheimer's disease.
- **Product Profile/Pipeline**
Neuronix continues to further develop its technology, widen its indications to other neurodegenerative conditions, as well as research into more effective treatment protocols and longer follow-ups.

What's Next?

Neuronix has submitted the neuroAD™ for US-FDA de-novo marketing clearance under the expedited access pathway (EAP) in Nov-2016, and expects to receive clearance during 2017Q4. Upon receiving FDA marketing clearance, Neuronix intends to commercially launch its technology across the USA, as well as broaden its penetration across European and Asian territories.